Summary
Results from a randomised European-Canadian trial showed that paclitaxel 175 mg/m2 infused as a 3-hour infusion is recommended in patients with platinum-refractory ovarian cancer. We assessed limited sampling models for relevant paclitaxel pharmacokinetic parameters using stepwise forward multiregression analysis for both area under the plasma concentration versus time curve from time 0 to 27 hours (AUC) and the time above a plasma threshold concentration of 0.1 µmol/L (T≥0.1 µmol/L) for the 3-hour infusion of 175 mg/m2. These strategies will be incorporated into future studies investigating pharmacokinetic/pharmacodynamic relationships of paclitaxel, using this dose and schedule. 24 pharmacokinetic curves were investigated from 24 patients with ovarian cancer treated with paclitaxel. 13 curves were selected by computer randomisation for the development of the model and the other 11 curves were used for the validation of the developed strategy. All patients received paclitaxel during a 3-hour infusion at a dosage of 175 mg/m2. Both pharmacokinetic parameters of interest, AUC and T≥0.1 µmol/L, could be predicted adequately with a 2-sample point model. This 2-point model, selected as optimal for the determination of the T≥0.1 µmol/L, was:
Using the best 2-point model for T≥0.1 µmol/L, a 2-point model was developed for estimating the AUC:
where C1h is the plasma concentration of paclitaxel at 1 hour after the end of a 3-hour infusion and C8h is the paclitaxel concentration at 8 hours after the end of the infusion.
Both models are predictive for T≥0.1 µmol/L (r2 = 0.91) and AUC (r2 = 0.92), and proved to be unbiased and precise for T≥0.1 µmol/L with a relative mean predictive error (MPE%) of −0.08 ± 1.94%, and a relative root mean square error (RMSE%) of 6.2% and for the estimation of the AUC (MPE% = −0.94 ± 2.49%, RMSE% = 7.9%).
For patients treated with paclitaxel at a dose of 175 mg/m2 given by a 3-hour infusion, the T≥0.1 µmol/L and the AUC of paclitaxel can be adequately estimated from two of the same timed plasma concentrations (C1h and C8h). These limited sampling strategies may greatly accelerate future studies on pharmacokinetic/pharmacodynamic relationships of paclitaxel in patients treated with 175 mg/m2 of the drug given as a 3-hour infusion.
Similar content being viewed by others
References
Schumacher GE. Choosing optimal sampling times for therapeutic drug monitoring. Clin Pharmacokinet 1985; 4: 84–92
Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology: problems and potential in antineoplastic therapy. Clin Pharmacokinet 1987; 13: 205–27
Van Warmerdam LJC, Ten Bokkel Huinink WW, Maes RAA, et al. Limited-sampling models for anticancer agents. J Cancer Res Clin Oncol 1994; 120: 427–33
Evans W, Relling MV. Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 1989; 16: 327–36
Grochow LB, Noe DA, Ettinger DS, et al. A phase I trial of trimetrexate glucorinate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics. Cancer Chemother Pharmacother 1989; 24: 314–20
Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci 1992; 13: 134–6
Rowinsky EK, Onetto N, Canetta RM, et al. Taxol: The first of the taxanes, an important new class of antitumor agents. Semin Oncol 1992; 19: 646–62
Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD, et al. European-Canadian randomized trial of taxol (paclitaxel) in relapsed ovarian cancer: high vs low dose and short vs long infusion. J Clin Oncol 1995; 12: 2654–66
Huizing MT, Keung ACF, Rosing H, et al. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum pretreated ovarian cancer patients. J Clin Oncol 1993; 11: 2127–35
Longnecker S, Ross D, Grochow L. High performance liquid Chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987; 71: 53–9
Brown T, Havlin K, Weiss G, et al. Phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol 1991; 9: 1261–7
Waugh W, Trissel L, Stella V. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991; 48: 1520–41
Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503–12
Rowinsky EK, Donehower RC, Jones RJ, et al. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093–100
Arbuck SG. Paclitaxel: What schedule? What dose? J Clin Oncol 1994; 12: 233–6
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huizing, M.T., van Warmerdam, L.J.C., Rosing, H. et al. Limited Sampling Strategies for Investigating Paclitaxel Pharmacokinetics in Patients Receiving 175 mg/m2 as a 3-Hour Infusion. Clin. Drug Invest. 9, 344–353 (1995). https://doi.org/10.2165/00044011-199509060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00044011-199509060-00005